Cargando…

Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Rafia, Shao, Huimin, Varamini, Pegah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864587/
https://www.ncbi.nlm.nih.gov/pubmed/36678741
http://dx.doi.org/10.3390/pharmaceutics15010112
_version_ 1784875620006625280
author Ali, Rafia
Shao, Huimin
Varamini, Pegah
author_facet Ali, Rafia
Shao, Huimin
Varamini, Pegah
author_sort Ali, Rafia
collection PubMed
description Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tumour progression, survival, and metastasis has been well elucidated. Focusing on cancer cells alone is no longer considered a viable approach to therapy; thus, there is a high demand for TME targeting. The benefit of using nanoparticles is their preferential tumour accumulation and their ability to target TME components. Several nano-based platforms have been investigated to mitigate microenvironment-induced angiogenesis, therapeutic resistance, and tumour progression. These have been achieved by targeting mesenchymal originating cells (e.g., cancer-associated fibroblasts, adipocytes, and stem cells), haematological cells (e.g., tumour-associated macrophages, dendritic cells, and myeloid-derived suppressor cells), and the extracellular matrix within the TME that displays functional and architectural support. This review highlights the importance of nanotechnology-based therapeutics as a promising approach to target the TME and improve treatment outcomes for TNBC patients, which can lead to enhanced survival and quality of life. The role of different nanotherapeutics has been explored in the established TME cell-driven populations.
format Online
Article
Text
id pubmed-9864587
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98645872023-01-22 Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations Ali, Rafia Shao, Huimin Varamini, Pegah Pharmaceutics Review Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tumour progression, survival, and metastasis has been well elucidated. Focusing on cancer cells alone is no longer considered a viable approach to therapy; thus, there is a high demand for TME targeting. The benefit of using nanoparticles is their preferential tumour accumulation and their ability to target TME components. Several nano-based platforms have been investigated to mitigate microenvironment-induced angiogenesis, therapeutic resistance, and tumour progression. These have been achieved by targeting mesenchymal originating cells (e.g., cancer-associated fibroblasts, adipocytes, and stem cells), haematological cells (e.g., tumour-associated macrophages, dendritic cells, and myeloid-derived suppressor cells), and the extracellular matrix within the TME that displays functional and architectural support. This review highlights the importance of nanotechnology-based therapeutics as a promising approach to target the TME and improve treatment outcomes for TNBC patients, which can lead to enhanced survival and quality of life. The role of different nanotherapeutics has been explored in the established TME cell-driven populations. MDPI 2022-12-29 /pmc/articles/PMC9864587/ /pubmed/36678741 http://dx.doi.org/10.3390/pharmaceutics15010112 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ali, Rafia
Shao, Huimin
Varamini, Pegah
Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
title Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
title_full Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
title_fullStr Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
title_full_unstemmed Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
title_short Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
title_sort potential nanotechnology-based therapeutics to prevent cancer progression through tme cell-driven populations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864587/
https://www.ncbi.nlm.nih.gov/pubmed/36678741
http://dx.doi.org/10.3390/pharmaceutics15010112
work_keys_str_mv AT alirafia potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations
AT shaohuimin potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations
AT varaminipegah potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations